PRFX (PainReform Limited) Company Cash Volume

Graphic logo of painreform.com (PRFX)

PainReform Ltd. (PRFX) lacks direct sales and pricing power due to the current clinical testing stage of its anesthesia formulas. Meanwhile, the modification of known molecules streamlines R&D, while the low-cost production of liquid forms under patent protection enhances operating leverage. The size of the cash reserve demonstrates a level of financial autonomy, with the latest figure standing at 0.00. The stability of future flows now depends exclusively on regulatory approval.

PRFX - PainReform Limited Company Total Cash Volume over the range 07/04/2022 - 11/21/2026

Financial and market metric breakdowns for PainReform Ltd (PRFX)

- stock value and consensus price forecast:
Fundamental company analysis:PainReform Ltd. PRFX
Signature product of PainReform

This metric reflects the share of liquid reserves relative to market capitalization, determining the asset's actual protection. Analyzing this proportion helps investors assess the risk of cash flow gaps or capital management inefficiencies. The cash volume trend on the chart visualizes the company's current financial stability. For PainReform Ltd. (PRFX), a sufficient cash reserve is critical when implementing innovations in non-opioid pain management. Liquidity ensures the development of extended-release drug technologies.

Direct competitors

Company Cash Funds Haleon (HLN)|Company Cash Volume Kenvue Inc. (KVUE)|Company Cash Volume VRNA (veronapharma.com)|Company Cash Balance MENS|LGND: Company Cash on Hand|Company Cash Balance AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Company Cash on Hand|Alvotech - Company Cash Balance|Company Cash on Hand LQDA|Galapagos Genomics (GLPG) - Company Liquid Assets|Company Cash Volume ANIP|Company Cash on Hand Afrezza MNKD|Company Cash Funds Amphastar AMPH|Company Liquid Assets Pacira BioSciences (PCRX)|ARS Corp - Company Cash Volume|TBPH: Company Cash Funds|AQST: Company Cash Volume|SCPH - Company Liquid Assets|TECX (Tectonic) - Company Cash Volume|Company Cash Reserve Tonix Pharmaceuticals Holding Corp. TNXP|Company Cash Funds SXT Pharmaceuticals (SXTC)|Company Cash Volume Eupraxia Pharmaceuticals Inc. (EPRX)|Company Cash Funds BioHarvest Sciences BHST|EXOZ (Invizyne) - Company Total Cash Volume|ORMP: Company Cash on Hand|ENTX (Entera Bio Ltd) - Company Cash and Cash Equivalents|HYFT: Company Cash Volume|Company Cash on Hand ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Company Cash Volume|Company Cash Funds QNTM|Company Cash Volume FGEN|Company Cash on Hand Telomir Pharmaceuticals TELO|Company Cash Volume RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Company Total Cash Volume|RLYB - Company Cash Funds|LEXX (Lexaria Bioscience Corp.) - Company Cash and Cash Equivalents|pulmatrix.com (PULM) - Company Cash Funds|PTHL (Pheton) - Company Cash Funds|Company Cash Funds Aptorum|Company Cash Reserve Lyra Therapeutics Inc. LYRA|Company Cash Volume IBO|TNFA (TNF Pharmaceuticals, Inc.) - Company Cash Balance|Company Cash Funds cbdMD, Inc. YCBD|CYTO (Auris Medical) - Company Total Cash Volume|LIPO - Company Cash Funds|Company Cash Balance OPTN (OptiNose)|PIRS: Company Cash Volume|Procaps Group S.A. (PROC) - Company Cash Volume|PTPI (Petros Pharma) - Company Cash Volume|QLI: Company Cash Balance|Company Cash Volume SLRN|TFFP (TFF Pharmaceuticals Inc.) - Company Cash Balance